Publication of the results of our study on expectations regarding a robotic arm and actual experiences following the provision of the innovative robotic assistive device (digitROBOT) for amyotrophic lateral sclerosis (ALS). Users’ experiences highlight the wide range of potential applications for robotic arms in ALS. The positive user experiences and high levels of satisfaction demonstrate that robotic arms represent a valuable treatment option for ALS patients with severe motor deficits in their arms.

This study demonstrates the association between ALS phenotypes and serum neurofilament light chain (NfL) levels, disease progression, and survival. ALS phenotypes have a significant influence on serum NfL levels and should be considered as an independent factor in NfL analyses in studies and in clinical practice.

A study involving 14 ALS outpatient clinics examined the diagnostic value of serum neurofilament light chain (sNfL) in ALS across a broad spectrum of disease courses in terms of disease progression and duration.

Publication on the use of the ALS Functional Rating Scale (ALSFRS-R) via a web portal or the ALS app. The study analyzed data from 620 people with ALS who completed the ALS Functional Rating Scale digitally. The result was impressive: those affected completed the ALS Functional Rating Scale digitally 9.6 times per year.

Publication of the results of our study on the benefits of therapeutic exercise trainers (digitTHERA) for amyotrophic lateral sclerosis (ALS). Between February 2019 and January 2021, data from 144 people with ALS who use an exercise trainer were collected and analyzed at 10 ALS centers in Germany.

In this study, 151 adult patients with 5q-SMA, representing a wide range of ages, disease duration, and motor function deficits, received nusinersen. Expectations regarding treatment with nusinersen varied widely and were related to disease severity and the pattern of symptoms and impairments. The majority of patients experienced relief from symptoms and motor deficits that was rated as mild or moderate. Despite the relatively modest extent of the perceived functional improvements, treatment satisfaction was high and recommendation rates were excellent.

Freie Universität Berlin, the University of Münster, and the Einstein Center Digital Future have conducted research on our digital service and research platform. The results have been published in a paper intended for an international audience.

A scientific study of symptomatic treatment with medications for amyotrophic lateral sclerosis (ALS). The study analyzed data from 2,392 people with ALS who participated in our digitally supported medication management program.

In this study involving 37 patients with ALS, THC:CBD was used across a wide range of doses to treat spasticity. The data suggest that the medication was administered based on the patients’ individual needs and preferences. Overall satisfaction with THC:CBD treatment was high. The results indicate that THC:CBD is a valuable addition to the range of symptomatic therapies for spasticity in people with ALS.

We surveyed 256 people with ALS between July 2014 and August 2017 regarding their access to medical treatments. Analysis of the data shows that ALS patients’ satisfaction with physical therapy, occupational therapy, and speech therapy is generally high.

The provision of assistive devices at 12 leading German ALS centers was evaluated over a four-year period. Data from 1,494 ALS patients, representing 11,364 instances of assistive device provision, were analyzed using the Ambulanzpartner care platform.

NeuroTransmitter serves as a discussion forum and a leading professional policy publication for neurologists and psychiatrists in Germany. With this article, we aim to provide comprehensive information and foster a solid understanding among outpatient care partners within our target audience.

An initial scientific analysis of aggregated care data from the Ambulanzpartner network. For the first time, data from digitized care processes provide an independent, direct comparison of health insurance plans’ benefits in the area of assistive devices for people with ALS.

The journal “Clinical Neurophysiology” is aimed at neurophysiologists, neurologists, neurosurgeons, and neurologists working in hospitals and private practices. The article provides a detailed description of “Ambulanzpartner” using the example of care for people with amyotrophic lateral sclerosis (ALS).